Encouraging results for PD-1 inhibition in gastric cancer

The Lancet Oncology

Volumn 17, Issue 6, 2016, Pages 682-683

  Smyth, Elizabeth C ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MELANOMA; MICROSATELLITE INSTABILITY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH TUMOR;

B7-H1 ANTIGEN; HUMANS; STOMACH NEOPLASMS;

EID: 84964723135     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30094-8     Document Type: Note

References (9)

1. 1 Bang, YJ, Van Cutsem, E, Feyereislova, A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010), 687–697.
2. 2 Wilke, H, Muro, K, Van Cutsem, E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15 (2014), 1224–1235.
3. 3 Ohtsu, A, Shah, MA, Van Cutsem, E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29 (2011), 3968–3976.
4. 4 Waddell, T, Chau, I, Cunningham, D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14 (2013), 481–489.
5. 5 Muro, K, Chung, HC, Shankaran, V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol, 2016 published online May 3. http://dx.doi.org/10.1016/S1470-2045(16)00175-3.
6. 6 Ford, HE, Marshall, A, Bridgewater, JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15 (2014), 78–86.
7. 7 Le, DT, Bendell, JC, Calvo, E, et al. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): results from the CheckMate-032 study. Proc Am Soc Clin Oncol, 34(suppl 4S), 2016 abstr 6.
8. 8 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014), 202–209.
9. 9 Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.